Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Evidence for a minimal eukaryotic phosphoproteome?
PMID 17712425 · PMC1945084 · PloS one · 2007 · 8 claims · 3 setups
Divergence in eukaryotic kinases at the primary sequence level is not reflected at the level of substrate phosphorylation.
-
Full-text index only
Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA.
PMID 18955570 · PMC2585845 · The Journal of experimental medicine · 2008 · 7 claims · 8 setups
Familial primary PAP is caused by compound heterozygous mutations in CSF2RA: a paternal G174R point mutation and a maternal 1.6-Mb deletion at Xp22.33 encompassing CSF2RA.
-
Has reproduction · 48
Irisin ameliorates obesity and insulin resistance via adipose tissue IL-33 and regulatory T cells.
PMID 41933175 · PMC13052164 · Nature metabolism · 2026 · 8 claims · 8 setups
Irisin modulates adipose tissue inflammation by increasing IL-33 production and preserving ST2+ regulatory T cells in white adipose tissues, thereby improving obesity and glucose intolerance.
-
Full-text index only
Generation of a restriction minus enteropathogenic Escherichia coli E2348/69 strain that is efficiently transformed with large, low copy plasmids.
PMID 18681975 · PMC2518929 · BMC microbiology · 2008 · 8 claims · 7 setups
E2348/69 possesses a type I restriction-modification system encoded by an hsdMSR-like operon identified by homology to known Hsd proteins.
-
Full-text index only
Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy.
PMID 18212748 · PMC2243141 · British journal of cancer · 2008 · 5 claims · 6 setups
LC-MS/MS proteomic analysis of stage I lung adenocarcinoma specimens identified myosin IIA and vimentin as candidate biomarker proteins with signal intensities that differed significantly among patient outcome groups